Can a single injection melt belly fat? a new trial aims to find out
NCT ID NCT07749742
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing an investigational drug called MI226, given as a single injection into belly fat, to see if it is safe and tolerable. The study involves about 52 adults with noticeable abdominal fat accumulation. Researchers will monitor for side effects and how the drug moves through the body, but this phase is primarily about safety, not whether it actually reduces fat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MI226 injection
- What this could lead to
- If safe and effective, MI226 could offer a non-surgical option to reduce abdominal fat, potentially improving body contour and metabolic health.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not fat reduction. The treatment may not work as hoped, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL FAT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.